Navigation Links
Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with gastro-esophageal reflux disease (GERD), a highly prevalent condition with a significant unmet medical need. The study achieved its primary objective, the control of 24-hour esophageal pH, with statistical significance, and also showed statistically significant improvements in many of the secondary measures, including clinical symptoms of GERD. ADX10059 is also in clinical development in two other indications, migraine and anxiety.

Patients with GERD have a dysregulation of lower esophageal sphincter function, resulting in inappropriate relaxation of the sphincter muscle and causing reflux of stomach contents into the esophagus, particularly after meals and at night. Pre-clinical pharmacology studies have shown that metabotropic glutamate receptor 5 (mGluR5) inhibition reduces transient sphincter relaxation episodes, improves muscle tone of the lower esophageal sphincter, and prevents reflux of stomach contents into the esophagus. As ADX10059 is a selective mGluR5 negative allosteric modulator, it may have the possibility to reduce inappropriate esophageal sphincter relaxations and prevent reflux in man. Hence, a proof of concept study of the effect of this compound on gastro-esophageal reflux in patients with GERD was performed.

The single-blind, placebo-controlled, two-day study was performed in 24 male and female patients. The objectives were to evaluate the effect of ADX10059 on physiological measures of reflux, using continuous 24-hour pH recording in the lower esophagus, and on the occurrence of patient-recorded clinical symptoms of GERD. On Day 1 patients received placebo, while on Day 2 they received ADX10059 half an hour before each of three meals. The patients were unaware of the treatment sequence. D
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
7. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
8. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
Post Your Comments:
(Date:10/8/2008)... Reduce Animal Use in Cosmetics and Chemicals Test...k Corp. today announced,that results of a recently...-up" validation study on MatTek,s EpiDerm in vitro...monstrated the required sensitivity and,specificit...ative to animal,testing for determining human skin...
(Date:10/8/2008)...nstitute Pioneers Research That May Offer New Hope...wswire/ -- Nationally, over 3,000 people are,waiti...e. Sadly, only half,of those will receive a transp...stitute (AHI) is paving the way for how to treat c...the Multimedia News Release, go to:, http://www.pr...
(Date:10/8/2008)...rsity Food Scientists Expand Testing Using Cellula..., PORTLAND, Maine, Oct. 8 /- Wild Bl...he release of results from a new study,showing Wil...consumed,fruits like apples, bananas, red grapes a...ular Antioxidant Activity (CAA) assay. New researc...
(Date:10/8/2008)...Confirm Potency of Poly-ICR as Vaccine Adjuvant, ... Biopharmaceuticals,Corporation (TSX: NVN) today p...ing its proprietary Toll-like Receptor 3 agonist, ...cine Congress 2008 in Lyon, France.,Study results ...ant,targeting the Toll-like Receptor 3 (TLR3) path...
Breaking Medicine Technology:MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Hurried doctor visits may leave patients feeling forgetful 22772 1Hurried doctor visits may leave patients feeling forgetful 22772 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 1Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 2Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 3Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards 22766 4Christine Poon Will Keynote MichBio Expo 6210 1Christine Poon Will Keynote MichBio Expo 6210 2Christine Poon Will Keynote MichBio Expo 6210 3 TraumaCure Receives Prestigious ISO 13485 Certification 6209 1 TraumaCure Receives Prestigious ISO 13485 Certification 6209 2
...d today shows reduction of 70,percent in spine fra...ER, N.J., May 02, 2007 /PRNewswire/ -- A once-year...tion significantly,reduced the incidence of all ty...s in women with postmenopausal osteoporosis. This,...of Medicine,marks the first time that an osteopor...
...- Bayer HealthCare,Pharmaceuticals announced today...ron(R) (interferon beta-1b), presented this week,a...nnual Meeting,demonstrating early efficacy, long-...ith treatment in patients with relapsing,forms of ...udies highlight the important clinical,benefits an...
Other Medicine Technology:Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 2Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 3Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 4Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 5Once-yearly Reclast Significantly Reduced Bone Fractures in Women,with Postmenopausal Osteoporosis 6Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...fare, Indian scientists have been sequencing the g...It is India's first sequencing effort of a complet...several diseases, including tuberculosis and lepro...de from killed Mw drastically reduces treatment ti...
...fer from migraine are more at risk of heart attack...ological condition, of which the most common sympt... Men with migraines were more likely to have high...d cholesterol levels, compared to men who didn't h...
...a bacterium, which is one of the leading cause for...ing cause for blindness globally, is said to be// ...ve imagined. The scientists from Children’s Hospi...ere the first to conclude this with the help of a ...
...two important changes that revolve around prematur...ch-greater ability of medical advances to keep// a...nge that has been noted is the increased rate of p...e births resulting from fertility treatment. A re...
Other Medicine News:Health News:India Finds New Use for an Old Bug 2Health News:India Finds New Use for an Old Bug 3Health News:Newly Identified Strains Of Chlamydia Trachomatis – A Gateway To New Disease 2Health News:Premature Babies- What should be done about them? 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: